Genexol-PM is an injectable chemotherapy medication that contains paclitaxel, a potent anticancer agent. Unlike traditional paclitaxel formulations, Genexol-PM utilizes a nanoparticle albumin-bound (nab-paclitaxel) technology. This formulation encapsulates paclitaxel in albumin-bound nanoparticles, allowing for improved solubility and delivery of the drug to tumor cells. Genexol-PM is administered intravenously and is used in the treatment of various cancers.

Mechanism of Action

Paclitaxel, the active component in Genexol-PM, functions by:

• Stabilizing microtubules: Paclitaxel binds to microtubules, stabilizing them and preventing their depolymerization.

• Inhibiting cell division: By stabilizing microtubules, paclitaxel disrupts the normal function of the mitotic spindle, leading to cell cycle arrest and apoptosis (programmed cell death).

  Uses

  Genexol-PM is indicated for the treatment of:

  • Ovarian Cancer: To treat advanced or recurrent ovarian cancer.

  • Breast Cancer: Particularly in cases where the cancer has metastasized or recurred.

  • Non-Small Cell Lung Cancer (NSCLC): For advanced stages of NSCLC.

  • Kaposi’s Sarcoma: Especially in patients with acquired immunodeficiency syndrome (AIDS).

    Adverse Effects

    Common side effects associated with Genexol-PM include:

    • Gastrointestinal issues: Nausea, vomiting, diarrhea, constipation.

    • Hematologic effects: Neutropenia (low white blood cell count), anemia, thrombocytopenia (low platelet count).

    • Fatigue: Generalized tiredness and weakness.

    • Hair loss: Alopecia, which is typically reversible after treatment completion.

    • Neurological symptoms: Peripheral neuropathy, including tingling or numbness in extremities.

    • Hypersensitivity reactions: Allergic reactions, including rash, fever, and chills.